Refine by
Cardiovascular System Articles & Analysis: Older
36 news found
They have strong biological activities and are able to constrict blood vessels in the cardiovascular system and protect against X-ray radiation. Hordenine and syfinerine are the two most common phenylethylamine alkaloids. ...
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. ...
The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure. ...
ByBayer AG
The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
– February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel ...
” More specifically, the testing range of T,C&A Lab encompasses the following: l Repair materials for the skeletal-muscle system such as bones, teeth, joints, and tendons l Soft tissue materials such as skin, esophagus, respiratory tract, bladder and other l Cardiovascular system materials such as artificial heart valves, blood ...
Inflammation can contribute to the physical decline in Aging Frailty through multiple mechanisms, including detrimental effects on muscles, bone tissue, the immune system, cardiovascular function, and cognition. The necessity for identifying patients with Aging Frailty is well-acknowledged in the geriatric community, and the treatment of Aging Frailty and ...
“The catheter is the first platform to score plaque, crack calcium and provide grip to secure position in the lesion during inflations without metallic components,” said Mitch Krucoff, MD, and Professor of Medicine/Cardiology and Director, Cardiovascular Devices Unit, Duke University Medical Center. “This novel design thus brings unique profile, deliverability, ...
Location: Caesarea, Israel and Agoura California V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devicesfor treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has successfully closed all remaining tranches of the Series C extension totaling $98M. ...
EBR Systems’ WiSE™ CRT System is world’s first and only wireless endocardial (inside the heart) left ventricle pacing system for heart failure EBR’s AU$110m ASX initial public offering today was strongly supported by new and existing institutional shareholders The new capital funds the completion of pivotal study, ...
Before Onset, Bishop served as Vice President of Research and Development for Endologix, Inc. and held management and engineering positions at Radiance Medical Systems, CardioVascular Dynamics Inc., and Guidant (Advanced Cardiovascular Systems). ...
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved Xplore2/Pivotal study. ...
AdjuCor raises € 29 million to enable its next phase of bringing its revolutionary heart assist technology to the severely underserved end-stage heart failure patients. This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor ...
BOSTON – Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, today announced $8 Million in Series A financing led by MedTex Ventures and Global Health Impact Fund. New and existing investors Checkmate Capital, IAG Capital, BlueStone Venture Partners, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, ...
ByElucid
– April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that ...
Xeltis CEO Eliane Schutte has been included in the Healthcare Technology Report’s list of 2021 Top 50 Healthcare Technology CEOs, one of only seven women featuring on the list. The Report’s list recognizes the most accomplished executives in the healthcare technology, whose leadership has been critical in developing industry leading medical devices, next generation software ...
– March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology. ...
– January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. ...
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. ...
ByRobocath